EUVIMEDEUVIMED entdecken
Crossref

Ruxolitinib Alleviates Inflammation and Fortifies Skin Barrier Function Through Dampening IL ‐13

Li Fang Koh iD, Muhammad Jasrie Firdaus, Yohei Natsuaki, Sho Hanakawa, Khek-Chian Tham iD, Declan P Lunny, Belle L H Yap, Satoshi Nakamizo iD, Eori Nam, Ji Eun Lee, Ying Xiu Toh, Nelson M H Teo und 5 weitere

Experimental Dermatology · 2025

DOI: 10.1111/exd.70132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, 2025. Verfasst von Li Fang Koh und 16 weiteren Autor:innen. Beteiligte Einrichtung: A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore. Hauptthemen laut MEDLINE: Pyrazoles, Dermatitis, Atopic, Interleukin-13, Skin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: A*STAR-BMRC-EDB (IAF-ICP and IAF-PP grants), National Medical Research Council (Open Fund - Large Collaborative Grant), A*STAR Biomedical Research Council [(Central Research Funds (Applied Translational Research)].

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a prevalent inflammatory skin disorder characterized by an impaired skin barrier, dysregulated immune system and pruritis. Emerging pharmaceutical therapies for AD include selective Janus kinase (JAK) inhibitors such as ruxolitinib, the first dual JAK1/JAK2 inhibitor approved by the US Food and Drug Administration. This study aimed to evaluate the effects of ruxolitinib on AD‐related symptoms using mouse and human skin models. AD‐related symptoms were assessed in MC903/ruxolitinib‐treated mice, including ear swelling, histological analysis, pruritus, serum biomarker quantification and immune cell analysis. Additionally, immunohistochemistry and transcriptome analysis were conducted on AD‐related cytokine‐treated reconstructed human skin (RHS) and ruxolitinib‐treated human skin explants with and without tape‐stripping. Ruxolitinib‐treated mice exhibited reduced inflammation, including decreased ear swelling and diminished pruritus. Furthermore, reductions in immune cell populations, including T cells and serum biomarker IL‐13, were observed in ruxolitinib‐treated mice. Transcriptome analysis revealed increased STAT3 expression and decreased skin barrier gene FLG in AD‐related cytokine‐treated RHS. Regardless of tape stripping, ruxolitinib‐treated skin explants exhibited decreased IL13RA1 expression and increased expression of skin barrier genes FLG , FLG2 and LOR . Ruxolitinib treatment in mice resulted in decreased inflammation and pruritus, along with increased expression of skin barrier proteins through downregulation of IL‐13. Consistently, ruxolitinib‐treated human skin explants demonstrated enhanced expression of skin barrier proteins, while IL‐13 treatment of RHS led to downregulation of these proteins. These findings support data from human clinical trials indicating reduced SCORAD, pruritus and inflammatory phenotypes in AD patients treated with ruxolitinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesDermatitis, AtopicInterleukin-13SkinNitrilesPyrimidinesAnimalsHumansMiceFilaggrin ProteinsJanus Kinase InhibitorsDisease Models, AnimalFemaleSTAT3 Transcription FactorInflammationPruritus

Stichwörter der Autor:innen

JAK/STATMC903atopic dermatitisreconstructed human skinruxolitinibskin explants

Substanzen

ruxolitinibPyrazolesNitrilesPyrimidinesFilaggrin ProteinsInterleukin-13FLG protein, humanJanus Kinase InhibitorsSTAT3 Transcription Factor

Autor:innen und Institutionen

  • A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Skin Research Institute of Singapore (SRIS), Singapore, Singapore.
  • JW C&C Research Laboratories, Seoul, Republic of Korea.
  • Department of Plastic, Reconstructive and Aesthetic Surgery, National University Hospital (NUH), Singapore.
  • Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

ORCID-Profile: Li Fang Koh, Khek-Chian Tham, Satoshi Nakamizo, E Birgitte Lane, Kenji Kabashima, John E Common

Förderung

  • A*STAR-BMRC-EDB (IAF-ICP and IAF-PP grants)
  • National Medical Research Council (Open Fund - Large Collaborative Grant)
  • A*STAR Biomedical Research Council [(Central Research Funds (Applied Translational Research)]
  • JW Pharmaceuticals, C&C Research Laboratories
  • Agency for Science, Technology and Research
  • Economic Development Board - Singapore

Zitieren

APA

Koh, L. F., Firdaus, M. J., Natsuaki, Y., Hanakawa, S., Tham, K. C., Lunny, D. P., Yap, B. L. H., Nakamizo, S., Nam, E., Lee, J. E., Toh, Y. X., Teo, N. M. H., Lim, T. C., Lane, E. B., Kabashima, K., Janela, B., & Common, J. E. (2025). Ruxolitinib Alleviates Inflammation and Fortifies Skin Barrier Function Through Dampening IL ‐13. Experimental Dermatology. https://doi.org/10.1111/exd.70132

Vancouver

Koh LF, Firdaus MJ, Natsuaki Y, Hanakawa S, Tham KC, Lunny DP, et al. Ruxolitinib Alleviates Inflammation and Fortifies Skin Barrier Function Through Dampening IL ‐13. Experimental Dermatology. 2025. doi:10.1111/exd.70132

BibTeX
@article{Koh2025,
  author = {Koh, Li Fang and Firdaus, Muhammad Jasrie and Natsuaki, Yohei and Hanakawa, Sho and Tham, Khek-Chian and Lunny, Declan P and Yap, Belle L H and Nakamizo, Satoshi and Nam, Eori and Lee, Ji Eun and Toh, Ying Xiu and Teo, Nelson M H and Lim, Thiam Chye and Lane, E Birgitte and Kabashima, Kenji and Janela, Baptiste and Common, John E},
  title = {Ruxolitinib Alleviates Inflammation and Fortifies Skin Barrier Function Through Dampening IL ‐13},
  journal = {Experimental Dermatology},
  year = {2025},
  doi = {10.1111/exd.70132}
}
Kostenlos starten →